Recursion Pharmaceuticals has raised $60 million to step up its artificial intelligence-enabled drug discovery activities. The series B equips Recursion to move beyond its initial focus on repurposing ...

Some new investors pitched in to Recursion Pharmaceuticals Inc.'s $121 million series C financing, adding to the industry's vision of the importance of AI and machine learning. The round was led by ...

SALT LAKE CITY--(BUSINESS WIRE)--Recursion, a next-gen biopharma company combining automated, experimental biology with artificial intelligence to discover and develop drugs at scale, today announced ...

Recursion Pharmaceuticals Inc., a biotech company leveraging artificial intelligence to discover new therapies, has raised a $60 million series B financing led by the Silicon Valley-based venture firm ...

Digital drug-discovery startup Recursion Pharmaceuticals Inc. has formed a partnership with Bayer AG that could be worth more than $1 billion and also raised a $239 million venture financing round led ...

Recursion Pharmaceuticals LLC has raised $12.9 million in Series A financing on the promise that it can convert drugs idling on pharmaceutical companies’ shelves into therapies for rare diseases. is ...